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Abstract
Purpose Patients with type 2 diabetes (T2DM) have increased fracture risk. Osteopontin (OPN) is a protein involved in 
bone remodeling and inflammation. The aim of this study was to evaluate the association of OPN with fracture prevalence 
and with metabolic parameters in post-menopausal women with T2DM.
Methods Sixty-four post-menopausal women with T2DM (age 67.0 ± 7.8 years, diabetes duration 8.9 ± 6.7 years), enrolled 
in a previous study, were followed up (3.6 ± 0.9 years). Previous fragility fractures were recorded. The FRAX score (without 
BMD) was calculated and biochemical parameters (plasma glucose, HbA1c, lipid profile and renal function) were assessed. 
Serum 25OH-vitamin D, calcium, PTH and OPN were evaluated at baseline. The association between OPN and fracture 
prevalence at baseline was evaluated by a logistic model.
Results OPN levels were higher in patients with previous fractures (n.25) than in patients without previous fractures at 
baseline (n.39) (p = 0.006). The odds of having fractures at baseline increased by 6.7 (1.9–31.4, 95% CI, p = 0.007) for each 
increase of 1 ng/ml in OPN levels, after adjustment for vitamin D and HbA1c levels. Fracture incidence was 4.7%. Higher 
OPN associated with a decrease in HDL-cholesterol (p = 0.048), after adjustment for age, basal HDL-cholesterol, basal and 
follow-up HbA1c and follow-up duration. 25OH-vitamin D associated with an increase in FRAX-estimated probability of 
hip fracture at follow-up (p = 0.029), after adjustment for age, 25OH-vitamin D and time.
Conclusions In post-menopausal women with T2DM, OPN might be a useful marker of fracture and worse lipid profile.
Keywords Osteopontin · Type 2 diabetes · Fracture risk · Lipid profile · FRAX tool · 25OH Vitamin D
Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease with 
increasing global prevalence. It can lead to macro- and 
microvascular complications, causing marked disability. It 
has also been demonstrated that patients with T2DM have 
higher fracture risk, compared with subjects without diabe-
tes [1–5]. Paradoxically, bone mineral density (BMD) is nor-
mal or even increased in most men and women with T2DM. 
Thus, the clinical utility of BMD in these patients has been 
questioned [2, 3]. On the other hand, the algorithms based 
on clinical risk factors, such as the most widespread FRAX 
algorithm [6], underestimate fracture risk in the high-risk 
population of patients with T2DM [7, 8]. These concern 
about the predictive role of the most commonly used diag-
nostic tools, stimulates to search for possible alternative 
markers of skeletal fragility in T2DM. Osteopontin (OPN) 
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is a non-collagenous matrix protein expressed in bone tissue, 
which is involved in bone remodelling and capable to acti-
vate bone resorption [9, 10]. In addition, OPN is a protein 
with pleiotropic physiological functions, involved in both 
acute and chronic inflammation [11] and there is increasing 
evidence about its role as a novel biomarker of cardiovascu-
lar risk in patients with T2DM [12].
The aim of this study was to evaluate the association 
between OPN and fracture prevalence, in a sample of post-
menopausal women with T2DM. Considering the possible 
role of OPN as a cardiovascular risk biomarker, in these 
patients we also longitudinally investigated the association 
between OPN circulating levels and some glyco-metabolic 
parameters.
Methods
Sixty-four post-menopausal women with T2DM (mean age 
67.0 ± 7.8 years, mean diabetes duration 8.9 ± 6.7 years), 
enrolled in a previous larger cross-sectional multicenter 
study [8], were followed up longitudinally in the outpatient 
clinics of Policlinico Umberto I, “Sapienza” University Hos-
pital of Rome. The previous multicenter study had recruited 
n.974 patients with T2DM and n.777 control subjects in 
three Italian outpatient clinics and was aimed to define 
whether distinct clinical profiles of patients with T2DM 
were associated with higher FRAX values. A sub-group 
of patients was selected for follow up, through the follow-
ing inclusion criteria: female sex; T2DM; post-menopausal 
status; age < 85 years. Exclusion criteria were as follows: 
reported diagnosis or pharmacologic therapy for osteoporo-
sis; all clinical conditions associated with secondary osteo-
porosis (endocrine, haematological, gastrointestinal, rheu-
matic and renal diseases); treatment with thiazolidinediones, 
methotrexate, antiepileptic agents, glucocorticoids, heparin 
and orlistat; drug and alcohol abuse; psychiatric diseases; 
malignant neoplasms. All patients gave written informed 
consent, the protocol was approved by the hospital ethics 
committee and was performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and 
its later amendments.
Both at enrolment and at follow-up visits a detailed medi-
cal history, including information about UV exposure [13], 
the recording of previous/incident fractures and major car-
diovascular events, a complete medical examination were 
performed and all medications were recorded. The FRAX 
scores (based on anthropometric data, without BMD meas-
urement) were calculated at baseline and at final visit [6]. 
All patients were also screened for the presence of T2DM 
complications (cardiovascular disease, diabetic retinopathy 
and neuropathy). Both at baseline and follow up, the follow-
ing biochemical parameters were assessed: fasting plasma 
glucose, HbA1c, lipid profile and renal function markers. 
GFR was estimated by the CKD-EPI equation [14]. Circu-
lating levels of 25OH-vitamin D, calcium, PTH and OPN 
were evaluated at baseline only. At follow up, all patients 
were asked about incident clinical fragility fractures from 
baseline.
General chemistry parameters were assessed by an auto-
mated multi-analyzer (Dimension Vista, Siemens technol-
ogy, USA). HbA1c was measured by HPLC (Menarini Diag-
nostics, Milan, Italy). The levels of 25OH-vitamin D and 
PTH were measured by an automated chemiluminescence 
immunoassay (ADVIA Centaur XP, Siemens technology, 
USA). OPN levels were determined with Enzyme-Linked 
Immunosorbent Assay by a commercially available assay 
(Abcam, UK). The intra-assay coefficient of variation was 
0.4% for calcium, 4.0% for PTH, 4.3% for 25OH-Vitamin D 
and < 10% for OPN.
Statistical analysis
Considering the samples of patients with fractures and with-
out fractures, a t test to compare the levels of OPN which 
allows to detect an effect size of 80% of the standard devia-
tion yields a power equal to 0.87 with a significance level of 
0.05. Continuous variables are expressed as mean ± stand-
ard deviation (SD) and categorical variables as percentage. 
For each variable normality was visually assessed. After 
normality testing, differences between baseline and follow 
up were evaluated by paired sample t-test for normally dis-
tributed continuous variables and by Mann–Whitney U test 
for not normally distributed continuous variables. Differ-
ences in values for categorical variables between baseline 
and follow-up were assessed using McNemar’s test. The 
association between OPN at baseline and the presence of 
fractures at baseline was evaluated by a logistic model. 
Stepwise elimination using Akaike Information Criterion 
(AIC) was performed, forcing the model to retain the covari-
ate 25OH-vitamin D and HbA1c at each iteration. A ROC 
curve analysis was performed to identify the optimal cut-
off of OPN associated with fragility fractures at baseline 
and the threshold was obtained selecting the highest point 
in the roc curve according to Younden’s Index. The asso-
ciation between 25OH-vitamin D, calcium, PTH and OPN 
values (covariates) at baseline, and percentage variation of 
variables (BMI, HbA1c, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, triglycerides, CKD-EPI, FRAX for major 
osteoporotic and for hip fracture) between baseline and fol-
low-up, were evaluated with a linear model, after adjusting 
for age, follow-up duration and basal value of each variable. 
In the model evaluating the effect of the covariates on the 
percentage variation of HDL-cholesterol, the results were 
also adjusted for variation of HbA1c, since glycemic control 
may influence HDL-cholesterol. A model has been estimated 
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for each percentage variation, resulting in 9 models. Step-
wise elimination for the covariates was applied using AIC to 
select the best model. The statistical analysis was performed 
using the software R package v. 3.3.2. A p value < 0.05 was 
considered statistically significant.
Results
Clinical and biochemical parameters of all patients are 
reported in Table 1. As shown, no significant differences 
in clinical and biochemical parameters were found between 
baseline and follow up. Differences in FRAX scores and 
CKD-EPI between baseline and follow-up were not signifi-
cant adjusting for age.
The prevalence of previous fragility fractures was 39.7% 
at basal evaluation. Three out of 64 patients reported new 
fragility fractures (a Colles’ fracture, a humeral fracture and 
a metatarsal fracture, respectively) during the study period. 
Thus, the fracture incidence was 4.7% (mean follow-up dura-
tion 3.6 ± 0.9 years) but the prevalence of fractured patients 
did not change during the follow-up because the three inci-
dent fractures occurred in women already reporting a previ-
ous fracture at baseline. No significant differences in clinical 
and biochemical parameters were found between patients 
with (n.25) and without (n.39) previous fractures, whereas 
basal OPN levels were significantly higher in the first group 
(0.82 ± 0.72 vs 0.36 ± 0.35 ng/ml, respectively, p = 0.006) 
(Table 2). In the logistic model, the odds of having fractures 
at baseline increased by 6.7 (1.9–31.4, 95% CI, p = 0.007) 
for each increase of 1 ng/ml in OPN levels, after adjustment 
for 25OH-vitamin D levels and HbA1c (Table 3).
A ROC curve analysis was performed to identify the 
optimal cut-off of OPN associated with fragility fractures at 
baseline. Using a threshold of 0.33 ng/ml of OPN a classifier 
with specificity equal to 72% and sensitivity equal to 76% 
was obtained. The area under the curve was 0.708 (Fig. 1). 
Clinical and biochemical parameters of patients grouped 
on the basis of OPN cut-off value are reported in Table 4. 
As reported, no significant differences in clinical and bio-
chemical parameters were observed between patients with 
OPN levels above and below 0.33 ng/ml, except for fracture 
prevalence.
Higher values of OPN at baseline were also significantly 
associated with a decrease in HDL-cholesterol levels at fol-
low-up (p = 0.048), after adjustment for age, basal values of 
HDL-cholesterol, basal and follow-up values of HbA1c and 
duration of follow-up.
Mean serum calcium and PTH levels were 9.6 ± 0.4 mg/
dl and 49.5 ± 32.7 pg/ml, respectively, whereas mean 
Table 1  Clinical and 
biochemical parameters
Data are expressed as mean ± SD or %
BMI body mass index, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, CKD EPI 
chronic kidney disease epidemiology collaboration, HDL high density lipoprotein, LDL low density lipo-
protein, PTH parathyroid hormone, OPN osteopontin
*p < 0.05; **p < 0.01; ***p < 0.001; †adjusted for age
Baseline Follow-up p Value
Age (years) 67.0 ± 7.8 70.3 ± 8.0 0.000***
Diabetes duration (years) 8.9 ± 6.7 11.8 ± 6.3 0.000***
Weight (kg) 75.6 ± 12.6 73.4 ± 14.4 1.0
BMI (kg/m2) 30.6 ± 5.0 30.2 ± 5.5 0.5
Cardiovascular disease (%) 8 11 0.5
Glycemia (mg/dl) 145.1 ± 38.3 150.4 ± 52.7 0.4
HbA1c (%) 7.1 ± 1.5 7.5 ± 1.1 0.3
Creatinine (mg/dl) 0.8 ± 0.2 0.9 ± 0.3 0.1
eGFR–CKD EPI (mL/min/1.73 m2) 77.2 ± 17.4 70.4 ± 23.1 0.5†
Total cholesterol (mg/dl) 178.5 ± 37.1 169.9 ± 32.4 0.6
HDL-cholesterol (mg/dl) 51.5 ± 11.4 52.2 ± 15.7 0.9
LDL-cholesterol (mg/dl) 99.9 ± 33.8 88.2 ± 29.4 0.8
Triglycerides (mg/dl) 135.2 ± 53.4 151.5 ± 54.2 0.2
FRAX Score (major osteoporotic fractures) 8.4 ± 4.7 14.3 ± 6.1 0.7†
FRAX score (hip fractures) 2.8 ± 2.7 4.3 ± 3.2 0.6†
25 OH vitamin D (ng/ml) 11.4 ± 5.9 – –
Calcium (mg/dl) 9.6 ± 0.4 – –
PTH (pg/ml) 49.5 ± 32.7 – –
OPN (ng/ml) 0.54 ± 0.57 – –
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levels of 25OH-vitamin D were insufficient in the study 
population (11.4 ± 5.9 ng/ml). None of the patients had 
received calcium and vitamin D supplementation at 
baseline and in the previous 6 months from baseline. In 
the longitudinal evaluation, after adjustment for age, of 
25OH-vitamin D levels and time of observation, basal 
25OH-vitamin-D values were significantly (p = 0.029) 
associated with an increase in the FRAX-estimated prob-
ability of hip fracture at follow-up visit.
Table 2  Clinical and 
biochemical parameters of 
patients with and without 
previous fracture
Data are expressed as mean ± SD or %
BMI body mass index, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, CKD EPI 
chronic kidney disease epidemiology collaboration, HDL high density lipoprotein, LDL low density lipo-
protein, PTH parathyroid hormone, OPN osteopontin
*p < 0.05; **p < 0.01; ***p < 0.001
Previous fracture (n. 25) No previous 
fracture (n. 39)
p Value
Age (years) 67.2 ± 8.2 67.0 ± 7.7 0.9
Diabetes duration (years) 9.7 ± 8.6 8.3 ± 5.1 0.4
Cardiovascular disease (%) 8.0 7.9 0.6
Diabetic neuropathy (%) 67 68 1.0
Diabetic retinopathy (%) 7.1 13.6 0.4
Insulin therapy (%) 37 45 0.4
Weight (kg) 76.3 ± 14.9 75.0 ± 10.9 0.7
BMI (kg/m2) 31.0 ± 5.6 30.4 ± 4.6 0.6
HbA1c (%) 7.3 ± 1.6 7.0 ± 1.4 0.4
eGFR–CKD EPI (mL/min/1.73 m2) 73.2 ± 18.3 80.0 ± 16.5 0.2
eGFR–CKD EPI < 60 ml/min/1.73 m2 (%) 33 27 0.7
Total cholesterol (mg/dl) 177.2 ± 31.6 179.3 ± 40.7 0.8
HDL-cholesterol (mg/dl) 51.0 ± 10.1 52.0 ± 12.3 0.8
LDL-cholesterol (mg/dl) 100.5 ± 31.1 99.5 ± 36.0 0.9
Triglycerides (mg/dl) 129.0 ± 38.2 139.6 ± 62.0 0.4
FRAX score (major osteoporotic fractures) 9.3 ± 5.4 7.6 ± 3.8 0.2
FRAX score (hip fractures) 3.2 ± 3.1 2.3 ± 2.1 0.3
25OH vitamin D (ng/ml) 11.2 ± 5.9 11.6 ± 6.1 0.8
Calcium (mg/dl) 9.5 ± 0.4 9.6 ± 0.4 0.3
PTH (pg/ml) 47.7 ± 39.3 50.7 ± 28.0 0.7
OPN (ng/ml) 0.82 ± 0.72 0.36 ± 0.35 0.006**
Table 3  Logistic regression for prediction of fractures at baseline
HbA1c glycated hemoglobin, OPN osteopontin
*p < 0.05; **p < 0.01; ***p < 0.001
Parameter p Odds ratio (95% CI)
25OH-vitamin D 0.490 0.9 (0.8–1.0)
HbA1c 0.184 1.3 (0.8–2.0)
OPN 0.007** 6.7 (1.9–31.4)**
Fig. 1  ROC curve for OPN and previous fractures at baseline. Using 
a threshold of 0.33 ng/ml of OPN a classifier with specificity equal to 
72% and sensitivity equal to 76% was obtained. The area under the 
curve was 0.708
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Discussion
In this study, levels of OPN were higher in post-menopausal 
women with T2DM with prevalent fractures than in patients 
without clinical fractures. The increased fracture risk despite 
normal or even higher BMD values is a pathogenetic unre-
solved paradox in patients with T2DM [15]. Such a lower 
reliability of BMD has been related to alteration in bone 
quality [15]. Moreover, non-skeletal factors could also 
heavily influence fracture risk [1, 15]. The clinical chal-
lenge of fracture risk estimate in T2DM patients is further 
compounded by the generally low predictive performance 
of FRAX, the most commonly used algorithm based on 
clinical factors [7, 8]. The results of our previous cross-
sectional multicenter study confirmed that patients with 
T2DM had higher fracture rate than control subjects, despite 
equal or even lower FRAX scores [8]. Given this scenario, 
any new useful tool to investigate fracture risk in T2DM 
patients could add to the current clinical practice. Several 
biochemical markers of bone metabolism have been shown 
to be reduced in T2DM, reflecting a low turnover rate, and 
are not useful to predict fracture risk in these patients [16]. 
The possible role of OPN on bone health is supported by 
several basic science and even clinical data. OPN seems to 
promote osteoclast function [9] but compared to the effect 
on bone resorption, much less is known about the role of 
OPN in bone formation. Interestingly, it has been observed 
that it might act as a negative regulator of pre-osteoblastic 
cell proliferation and differentiation in vitro [10]. At a hypo-
thetical level, the inhibitory effect of high OPN levels on 
osteoblasts might indirectly have a negative influence on 
osteoclast function. Thus, high OPN levels might be linked 
to low bone resorption and formation, in line with the low 
bone turnover pattern, observed in T2DM. However, a limit 
of this study is the lack of the determination of bone resorp-
tion and apposition markers. Further studies are needed to 
investigate this possible link between high OPN levels and 
low bone turnover in T2DM. Moreover, in clinical grounds, 
previous studies have shown a negative association between 
OPN and BMD in post-menopausal women [17, 18]. Since 
the number of incident fractures during the follow-up period 
was quite low (n = 3), we could not reasonably test the asso-
ciation between OPN levels and incident fractures. Although 
larger studies with longer follow-up duration are needed to 
confirm these findings, OPN measurement might be a useful 
marker of fracture risk in clinical practice.
As additional information, our data also showed an asso-
ciation between OPN and HDL-cholesterol. Even though we 
did not find any significant correlation with hard end-points, 
as myocardial infarction or stroke, this information has some 
speculative interest. It should be stressed that the significant 
association between OPN and HDL-cholesterol was con-
firmed after adjustment for HbA1c levels, since HDL-cho-
lesterol values are influenced by the degree of glycemic con-
trol [19]. This finding is relevant, because post-menopausal 
women are more prone to dyslipidemia and to increased 
cardiovascular mortality [20, 21], and the link between low 
HDL-cholesterol levels and increased coronary heart disease 
(CHD) morbidity and mortality is supported by consistent 
evidence [22, 23]. On the other hand, serum OPN has been 
reported to be increased in patients with atherosclerosis and 
myocardial infarction [23]. OPN can induce macrophage 
chemotaxis [24]. Thus, it may play an important role in sev-
eral chronic inflammatory conditions, including atheroscle-
rosis. In particular, it has been shown that circulating OPN 
might be a marker of early coronary vascular calcification in 
T2DM patients with asymptomatic coronary artery disease 
[25]. These findings seem to support the role of OPN as an 
emerging biomarker of cardiovascular risk in T2DM [12]. In 
line with our results, in a recent study, OPN levels were also 
found to be correlated to lower HDL-cholesterol in patients 
with type 1 diabetes [26]. Thus, circulating levels of OPN 
could be predictive of an unfavourable lipid profile and, con-
sequently, high cardiovascular risk in patients with T2DM.
Moreover, the results of this study show that, despite no 
significant difference in other parameters was found, low 
levels of 25OH-vitamin D were associated with a subsequent 
increase of FRAX-estimated fracture risk. Even if the FRAX 
Table 4  Clinical and biochemical parameters of patients grouped by 
ROC curve OPN cut-off
Data are expressed as mean ± SD or as frequency
BMI body mass index, HbA1c glycated hemoglobin, eGFR estimated 
glomerular filtration rate, CKD EPI chronic kidney disease epidemi-
ology collaboration, HDL high density lipoprotein, LDL low density 
lipoprotein
*p < 0.05; **p < 0.01; ***p < 0.001
OPN 
≤ 0.33 ng/ml 
(n. 34)
OPN 
> 0.33 ng/ml 
(n. 30)
p Value
Age (yeas) 65.6 ± 7.9 68.6 ± 7.5 0.2
Diabetes duration (years) 7.9 ± 4.1 10.1 ± 8.7 0.9
Cardiovascular disease (%) 5.8 10.0 0.8
Diabetic neuropathy (%) 59 53.3 0.5
Diabetic retinopathy (%) 17.6 10 0.4
BMI (kg/m2) 30.6 ± 5.0 30.6 ± 5.2 1.0
HbA1c (%) 7.2 ± 1.3 7.1 ± 1.7 0.4
eGFR–CKD EPI < 60 ml/
min/1.73 m2 (%)
12 20 0.7
Total cholesterol (mg/dl) 180.3 ± 38.0 176.2 ± 36.8 0.7
HDL-cholesterol (mg/dl) 52.1 ± 12.3 51.0 ± 10.5 0.6
LDL-cholesterol (mg/dl) 100.3 ± 32.0 99.4 ± 36.7 0.9
Triglycerides (mg/dl) 140.0 ± 60.0 129.5 ± 45.3 0.4
Previous fractures (%) 17.6 63.3 0.000***
Incident fractures n. 0 3 0.06
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algorithm was not set-up for the longitudinal monitoring of 
fracture risk, this result deserves some interest. In fact, it 
persisted after adjustment for age, and was largely due to 
both incident hip fractures in parents and to the incident 
fractures occurred in T2DM patients during the follow-up. 
Although firm conclusions cannot be drawn from these data, 
we speculate that the poor vitamin D status of these patients 
associates to a worsening estimated fracture risk profile in 
T2DM. If confirmed in larger series, our results could sug-
gest to integrate FRAX algorithm with vitamin D status in 
T2DM patients.
The limits of this study are the small sample size, the lack 
of BMD-based FRAX assessment and of systemic inflamma-
tion markers. However, the results are intriguing for future 
studies in this field.
Conclusions
In conclusion, in post-menopausal women with T2DM, OPN 
levels relate to prevalent fractures and to HDL-cholesterol 
changes over time, which could reflect a role of OPN in 
hypothetical pathways shared by different diabetic chronic 
conditions.
Acknowledgements This research did not receive any specific grant 
from funding agencies in the public, commercial, or no-for-26 profit 
sectors.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. 
This article does not contain any studies with animals performed by 
any of the authors.
Informed consent Informed consent was obtained from all individual 
participants included in the study.
References
 1. Carnevale V, Romagnoli E, D’Erasmo E (2004) Skeletal involve-
ment in patients with diabetes mellitus. Diabetes Metab Res Rev 
20(3):196–204
 2. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer 
ES, Ensrud KE, Study of Osteoporotic Fractures (SOF), the 
Osteoporotic Fractures in Men (MrOS), Health, Aging and Body 
Composition (Health ABC) et al (2011) Association of BMD 
and FRAX score with risk of fracture in older adults with type 
2 diabetes. JAMA 305(21):2184–2192. https ://doi.org/10.1001/
jama.2011.715
 3. Vestergaard P (2007) Discrepancies in bone mineral density 
and fracture risk in patients with type 1 and type 2 diabetes—
a meta-analysis. Osteoporosis Int 18(4):427–444. https ://doi.
org/10.1007/s0019 8-006-0253-4
 4. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) 
Systematic review of type 1 and type 2 diabetes mellitus and 
risk of fracture. Am J Epidemiol 166(5):495–505. https ://doi.
org/10.1093/aje/kwm10 6
 5. Fan Y, Wei F, Lang Y, Liu Y (2016) Diabetes mellitus and risk 
of hip fractures: a meta-analysis. Osteoporos Int 27(1):219–228. 
https ://doi.org/10.1007/s0019 8-015-3279-7
 6. Centre for Metabolic Bone Diseases. University of Sheffield 
UK. https ://www.sheff ield.ac.uk/FRAX/tool.jsp?lang=it. 
Accessed Jun 2016
 7. Giangregorio LM (2012) FRAX underestimates fracture risk in 
patients with diabetes. J Bone Miner Res 27:301–308
 8. Carnevale V, Morano S, Fontana A, Annese MA, Fallarino M, 
Filardi T et al (2014) Assessment of fracture risk by the FRAX 
algorithm in men and women with and without type 2 diabe-
tes mellitus: a cross-sectional study. Diabetes Metab Res Rev 
30:313–322
 9. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoen-
berger J, Rifas L et al (2003) Osteopontin deficiency produces 
osteoclast dysfunction due to reduced CD44 surface expression. 
Mol Biol Cell 14(1):173–189
 10. Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi 
DT et al (2004) Osteopontin is a negative regulator of prolif-
eration and differentiation in MC3T3-E1 pre-osteoblastic cells. 
Bone 34:799–808
 11. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, John-
sonR Hughes J (2002) Osteopontin—A molecule for all seasons. 
QJM 95:3–13
 12. van der Leeuw J, Beulens JW, van Dieren S, Schalkwijk CG, 
Glatz JF, Hofker MH et al (2016) Novel biomarkers to improve 
the prediction of cardiovascular event risk in type 2 diabetes 
mellitus. J Am Heart Assoc 5:e003048. https ://doi.org/10.1161/
JAHA.115.00304 8
 13. Hanwell HE, Vieth R, Cole DE, Scillitani A, Modoni S, Frusci-
ante V, Ritrovato G, Chiodini I, Minisola S, Carnevale V (2010) 
Sun exposure questionnaire predicts circulating 25-hydroxyvita-
min D concentrations in Caucasian hospital workers in southern 
Italy. J Steroid Biochem Mol Biol 121(1–2):334–337. https ://
doi.org/10.1016/j.jsbmb .2010.03.023  (epub 2010 Mar 16)
 14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, 
Feldman HI et al (2009) A new equation to estimate glomerular 
filtration rate. Ann Intern Med 150(9):604–612
 15. Carnevale V, Romagnoli E, D’Erasmo L, D’Erasmo E (2014) 
Bone damage in type 2 diabetes mellitus. Nutr Metab Cardio-
vasc Dis 24:1151–1157
 16. Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch 
B, Tiran A, Strele A et al (2006) Type 2 diabetes mellitus in 
nursing home patients: effects on bone turnover, bone mass, and 
fracture risk. J Clin Endocrinol Metab 91:3355–3363
 17. Cho EH, Cho KH, Lee HA, Kim SW (2013) High serum osteo-
pontin levels are associated with low bone mineral density in 
postmenopausal women. J Korean Med Sci 28(10):1496–1499. 
https ://doi.org/10.3346/jkms.2013.28.10.1496 (epub 2013 Sep 
25)
 18. Fodor D, Bondor C, Albu A, Simon SP, Craciun A, Muntean L 
(2013) The value of osteopontin in the assessment of bone min-
eral density status in postmenopausal women. J Investig Med 
61(1):15–21. https ://doi.org/10.2310/jim.0b013 e3182 76126 4
 19. Barbarossa G, Renzi A, D’Erasmo L, Gallo A, Grieco E, Rossetti 
M et al (2014) The relation between glycemic control and HDL-C 
in type 2 diabetes: a preliminary step forward? Diabetes Res Clin 
Pract 104:e26–e28
Journal of Endocrinological Investigation 
1 3
 20. Nakhjavani M, Morteza A, Esteghamati A, Khalilzadeh O, 
Zandieh A, Safari R (2011) Serum lipoprotein(a) levels are 
greater in female than male patients with type 2 diabetes. Lipids 
46:349–356
 21. Kautzky-Willer A, Kamyar MR, Gerhat D, Handisurya A, Stemer 
G, Hudson S et al (2010) Sex-specific differences in metabolic 
control, cardiovascular risk, and interventions in patients with 
type 2 diabetes mellitus. Gend Med 7:571–583
 22. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz 
H, Kannel WB (1998) Prediction of coronary heart disease using 
risk factor categories. Circulation 97:1837–1847
 23. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M (2003) Osteo-
pontin is released from the heart into the coronary circulation in 
patients with a previous anterior wall myocardial infarction. Circ 
J 67:742–744
 24. Gravallese EM (2003) Osteopontin: a bridge between bone and 
the immune system. J Clin Invest 112:147–149
 25. Berezin AE, Kremzer AA (2013) Circulating osteopontin as a 
marker of early coronary vascular calcification in type two diabe-
tes mellitus patients with known asymptomatic coronary artery 
disease. Atherosclerosis 229:475–481
 26. Barchetta I, Alessandri C, Bertoccini L, Cimini FA, Taverniti L, 
Di Franco M et al (2016) Increased circulating osteopontin levels 
in adult patients with type 1 diabetes mellitus and association with 
dysmetabolic profile. Eur J Endocrinol 174:187–192
